Increased risk for pancreatic cancer
Although, the detection of pancreatic cancer in the early stages (I and II) significantly improves the survival rate of the patients, general testing of the entire global population is not health economically justifiable.
Therefore, Immunovia together with pancreatic cancer Key Opinion Leaders in US and Europe have defined three groups that have an increased risk of developing pancreatic cancer. Within these three risk groups there is a greater need for routine investigation and testing.
The three risk groups for pancreatic cancer are:
- Familial/hereditary pancreatic cancer individuals who have a 2-132 increased risk of developing pancreatic cancer depending on their genetic profiles and other factors well defined in national and international guidelines
- New onset diabetes type II patients over 50 years who suffer a 6-8 times increased risk of developing pancreatic cancer within 1-3 years
- Vague but concerning symptom profiles where the clinicians suspects, or wants to rule out, pancreatic cancer
IMMray™ PanCan-d has the potential to aid in the diagnosis/surveillance of these three risk groups, by offering early detection of pancreatic cancer, while the tumor may still be resectable by surgery.